Matthew Herper, STAT

Matthew Herper

STAT

New York, NY, United States

Contact Matthew

Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.

Start free trial

Recent:
  • STAT
Past:
  • CNBC
  • Forbes

Recent articles by Matthew:

Pfizer to buy Biohaven for $11.6 billion, raising hopes for the broader biotech market

Pfizer said Tuesday that it will purchase Biohaven, a maker for migraine drugs, for $11.6 billion in cash in a deal that may help ease what has been a brutal bear market for biotechnology stocks. → Read More

Illumina, maker of a key tool for drug discovery, to try making new drugs itself

DNA sequencing giant Illumina announced that it would enter the field of drug discovery, a major shift for a company that, since its founding in 1998, has thrived instead by selling picks and shovels to the prospectors of biotech’s various gold rushes. → Read More

Gilead’s Dan O’Day is pharma’s most charming executive — but with his deals falling apart, charm may not be enough

Gilead's Dan O’Day has charisma and charm. What he lacks lately are clear wins in drug development. → Read More

Pfizer and FDA pull back from plan to expedite review of Covid-19 vaccine in young children

Plans to attempt to authorize the Pfizer/BioNTech Covid vaccine for children under 5 before full data are available appear to have run aground. → Read More

The fall of Eric Lander and the end of science’s 'big ego' era

The resignation of Eric Lander as President Biden’s lead scientific adviser is not just a blow to one president’s plans for advancing research, but a signpost on the death march of a certain way of doing science. → Read More

A San Diego biotech’s massive valuation turned heads. Now, mass layoffs raise questions

Biosplice, once the world’s most valuable biotech startup, is laying off nearly a quarter of its workforce. → Read More

Pfizer names new top development executive as Covid remakes the company

Pfizer, the company behind a Covid vaccine and a Covid pill, has named a new top development executive as Covid remakes the company. → Read More

‘Nowhere to hide’: As biotech stocks plummet, an industry is being reshaped by the fallout

Biotech investors, once the envy of Wall Street, have slipped into despondency. After a double-digit decline in 2021, the sector has fallen another 20% in the new year, erasing billions in value and leading even the most seasoned investors to question whether biotech has further to fall. → Read More

As Pfizer and BioNTech begin clinical trial of Omicron-based vaccine, timeline to authorization is unclear

Pfizer expects initial findings from the study, which will enroll 1,420 volunteers in three cohorts, to be available during the first half of 2022. How soon regulators could authorize an Omicron-specific vaccine is unclear. → Read More

Did veteran drug developer Hal Barron accomplish his mission at GSK?

Hal Barron was hired to turn around R&D at GSK four years ago. Did he accomplish his mission? → Read More

With $3 billion, biotech veterans launch a global company aimed at disease ‘reversal’

A team of biotech veterans say they have raised $3 billion to create a continent-spanning company that will aim to battle disease by reprogramming the fundamental machinery of living cells. It appears to be the largest venture capital fundraising effort in biotech history, based on a survey of data from Pitchbook. → Read More

Study raises doubts about rapid Covid tests’ reliability in early days after infection

A new study raises significant doubts about whether at-home rapid antigen tests can detect the Omicron variant before infected people can transmit the virus to others. → Read More

FDA authorizes Merck’s Covid-19 pill, but stresses its use should be limited

The FDA granted emergency authorization to Merck’s molnupiravir, an antiviral pill shown to reduce hospitalization and death in cases of Covid-19, the second such treatment to be authorized. → Read More

FDA authorizes Merck’s Covid-19 pill, but stresses its use should be limited

The FDA granted emergency authorization to Merck’s molnupiravir, an antiviral pill shown to reduce hospitalization and death in cases of Covid-19, the second such treatment to be authorized. → Read More

FDA authorizes Pfizer pill to treat Covid-19 in patients as young as 12

The Food and Drug Administration on Wednesday authorized Paxlovid, a pill developed and made by Pfizer, as a treatment for Covid-19, a significant step in the battle against the SARS-CoV-2 virus. → Read More

The tragedy of Johnson & Johnson’s Covid vaccine

Johnson & Johnson’s Covid vaccine was going to be the shot for the world. Now, under the weight of a mountain of bad PR, one wonders if the world will want it. → Read More

Pfizer's Covid pill remains 89% effective in final analysis, company says

In a 2,246-patient study, Pfizer's Covid pill retained the efficacy at preventing hospitalization and death it had shown in an interim study. → Read More

Pfizer’s vaccine chief on Omicron, boosters, and preparing for the unknown

STAT spoke with Pfizer’s head of vaccine research, Kathrin Jansen, about the latest data on the company's vaccine and Omicron. → Read More

City of Hope to buy Cancer Treatment Centers of America for $390 million

The merger combines a hospital system known for research with one better known for aggressive marketing of its services. → Read More

FDA panel narrowly recommends authorization of Merck Covid pill after day of tense discussion

A panel of experts convened by the FDA voted by a slim margin to recommend the agency authorize the Covid treatment developed by Merck and partner Ridgeback Biotherapeutics. → Read More